Day: March 28, 2023

HUHTAMÄKI OYJ MANAGERS’ TRANSACTIONS 28.3.2023 AT 10:00 EEST Huhtamäki Oyj – Managers’ Transactions____________________________________________Person subject to the notification requirementName: Sami PauniPosition: Other senior managerIssuer: Huhtamäki OyjLEI: 5493007050SJVMXN6L29Notification type: INITIAL NOTIFICATIONReference number: 27866/8/8 ____________________________________________Transaction date: 2023-03-27Outside a trading venueInstrument type: SHAREISIN: FI0009000459Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details(1): Volume: 5566 Unit price: 0 EUR Aggregated transactions (1):Volume: 5566 Volume weighted average price: 0 EUR HUHTAMÄKI OYJ Group Communications About Huhtamaki Huhtamaki is a leading global provider of sustainable packaging solutions for consumers around the world....

HUHTAMÄKI OYJ MANAGERS’ TRANSACTIONS 28.3.2023 AT 10:00 EEST Huhtamäki Oyj – Managers’ Transactions____________________________________________Person subject to the notification requirementName: Eric Le LayPosition: Other senior managerIssuer: Huhtamäki OyjLEI: 5493007050SJVMXN6L29Notification type: INITIAL NOTIFICATIONReference number: 27863/9/8 ____________________________________________Transaction date: 2023-03-27Outside a trading venueInstrument type: SHAREISIN: FI0009000459Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details(1): Volume: 7752 Unit price: 0 EUR Aggregated transactions (1):Volume: 7752 Volume weighted average price: 0 EUR HUHTAMÄKI OYJ Group Communications About Huhtamaki Huhtamaki is a leading global provider of sustainable packaging solutions for consumers around the world....

Hydro’s first quarter results 2023 will be released at 07:00 CET (01:00 EST, 06:00 UTC/GMT) on Friday, April 28, 2023. The quarterly report and presentation slides will be available on www.hydro.com at the same time.  President and CEO Hilde Merete Aasheim and Executive Vice President and CFO Pål Kildemo will host an audio webcast and a conference call in English at 08:30 CET the same day. There will be a Q&A session directly after the presentation. There will be no presentation or press conference at our corporate headquarters.  To listen to the presentation, please join the audio webcast.  To join the conference call and to ask questions, register your details using this registration link. Once registered, you will receive a separate email containing your dial-in number(s) and PINs. Investor contact: Line Haugetraa +4741406376...

HUHTAMÄKI OYJ MANAGERS’ TRANSACTIONS 28.3.2023 AT 10:00 EEST Huhtamäki Oyj – Managers’ Transactions____________________________________________Person subject to the notification requirementName: Thomas GeustPosition: Chief Financial OfficerIssuer: Huhtamäki OyjLEI: 5493007050SJVMXN6L29Notification type: INITIAL NOTIFICATIONReference number: 27869/8/8 ____________________________________________Transaction date: 2023-03-27Outside a trading venueInstrument type: SHAREISIN: FI0009000459Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details(1): Volume: 6039 Unit price: 0 EUR Aggregated transactions (1):Volume: 6039 Volume weighted average price: 0 EUR HUHTAMÄKI OYJ Group Communications About Huhtamaki Huhtamaki is a leading global provider of sustainable packaging solutions for consumers around the...

HUHTAMÄKI OYJ MANAGERS’ TRANSACTIONS 28.3.2023 AT 10:00 EEST Huhtamäki Oyj – Managers’ Transactions____________________________________________Person subject to the notification requirementName: Charles HéaulméPosition: Chief Executive OfficerIssuer: Huhtamäki OyjLEI: 5493007050SJVMXN6L29Notification type: INITIAL NOTIFICATIONReference number: 27871/8/8 ____________________________________________Transaction date: 2023-03-27Outside a trading venueInstrument type: SHAREISIN: FI0009000459Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details(1): Volume: 28961 Unit price: 0 EUR Aggregated transactions (1):Volume: 28961 Volume weighted average price: 0 EUR HUHTAMÄKI OYJ Group Communications About Huhtamaki Huhtamaki is a leading global provider of sustainable packaging solutions for consumers around...

Borregaard’s Annual Report for 2022, which also includes the Sustainability Report, is published today. A pdf-version and a zip file are attached this notice. To order a printed copy of the report, please go to www.borregaard.com. Borregaard ASASarpsborg, 28 March 2023 Contacts:Tone Horvei Bredal, Communications Director, +47 924 67 711Lotte Kvinlaug, Investor Relations Officer, +47 922 86 909 This information is subject to the disclosure requirements pursuant to Sections 5-5 and 5-12 of the Norwegian Securities Trading Act.  AttachmentsAnnual Report 20225967007LIEEXZXGYXC05-2022-12-31-en

Significantly Expands Its Resource Holdings Beyond Arkansas to Texas EL DORADO, Ark., March 28, 2023 (GLOBE NEWSWIRE) — Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE American: SLI) (FRA: S5L), a leading near-commercial lithium company, is pleased to announce that, as part of its significant resource expansion work in the East Texas Smackover region, it has sampled, to the best of its knowledge, the highest confirmed lithium grade brine in North America, with a grade of 634 mg/L lithium. In Standard Lithium’s experience, the grade of lithium in brine used for Direct Lithium Extraction (DLE) has a meaningful impact on both capital expenditures and operating costs in connection with the extraction process, with a higher grade typically resulting in lower overall costs. Dr. Andy Robinson, President and...

Data highlights potential neuroprotective, neurotrophic and anti-inflammatory effects of enhancing the HGF/MET system BOTHELL, Wash., March 28, 2023 (GLOBE NEWSWIRE) — Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today presented preclinical data highlighting the potential therapeutic benefits of fosgonimeton at the AD/PD™ 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD). “New therapeutic strategies for neurodegenerative diseases are urgently needed. Our presentations at AD/PD highlight a wide range of preclinical evaluations demonstrating the ability of fosgonimeton, or its active metabolite fosgo-AM, acting through...

Vivoryon Therapeutics N.V. Provides Progress Update on Varoglutamstat Clinical Development for the Treatment of Alzheimer’s DiseaseVIVIAD Phase 2b study in Europe on track for final data readout Q1/2024 Data from all 259 randomized patients presented at AD/PD show no on-target toxicity and no clinical signs of ARIA, broadening evidence for potential of varoglutamstat in AD to overcome the safety challenges of other drug classes Coding enrichment strategy successfully applied for improved baseline assessment of rescuable deficits in attention and working memory in the study cohort VIVA-MIND Phase 2 study in the U.S. steadily progressing and enrolling at 18 sites; status update expected in 2H/2023 DSMB provided unanimous recommendation to continue VIVIAD without modification to dosing regimen, supporting rationale for accelerated...